Pfizer company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A Yahoo Finance market note points to a shift in Pfizer’s (PFE) valuation picture, arguing the stock’s longer-term underperformance is no longer paired with the same degree of perceived “cheap” or “expensive” pricing.
THE APEX TIMES
THE APEX TIMES
The drugmaker says its once-daily LITFULO met positive topline readouts across two Phase 3 trials in patients with both active and stable nonsegmental vitiligo, though details of efficacy and safety were not included in the initial report.
THE APEX TIMES
The European Commission granted approval for an updated, XFG-adapted COVID-19 vaccine from Pfizer and BioNTech, covering use in people aged 6 months and older across the European Union for the upcoming seasonal rollout.
THE APEX TIMES
A market preview from Yahoo Finance says Pfizer (PFE) appears to have the right mix of factors to outperform analyst expectations when it releases second-quarter results, though the post offers limited details on the underlying drivers.
THE APEX TIMES
Pfizer (PFE) closed at $25.25 in the most recent session, up 2.35% from the prior day, according to market-tracking coverage.
THE APEX TIMES
Ahead of its Q2 earnings, Pfizer is likely to face investor scrutiny on growth drivers, the pace of demand recovery after COVID-era momentum faded, and how updated guidance could shift expectations for the full year.
THE APEX TIMES
The European Commission has granted marketing authorization for an updated Pfizer and BioNTech COVID-19 vaccine designed around the “XFG” formulation, according to a joint announcement reported by Yahoo Finance on July 29, 2026.
THE APEX TIMES
A recent market piece argued that Pfizer, long a bellwether in large-scale drug development and manufacturing, may fit investors’ screens for cheaper, income-oriented stocks, even as the sector continues to face ongoing pressure points.
THE APEX TIMES
A sharply higher dividend yield has investors focused on whether Pfizer can sustain large cash returns while facing revenue pressure from expiring patents.
